AEs according to treatment arm and in all patients treated with pola + BR
| AE . | Randomized, BR (n = 39) . | Pooled, pola + BR* (N = 151) . | ||
|---|---|---|---|---|
| All grade . | Grade 3-4 . | All grade . | Grade 3-4 . | |
| Neutropenia | 15 (38.5) | 13 (33.3) | 56 (37.1) | 49 (32.5) |
| Thrombocytopenia | 12 (30.8) | 9 (23.1) | 49 (32.5) | 31 (20.5) |
| Anemia | 10 (25.6) | 7 (17.9) | 49 (32.5) | 19 (12.6) |
| Infections and infestations† | 20 (51.3) | 8 (20.5) | 74 (49.0) | 33 (21.9) |
| Diarrhea | 11 (28.2) | 2 (5.1) | 54 (35.8) | 6 (4.0) |
| Nausea | 16 (41.0) | 0 | 50 (33.1) | 1 (0.7) |
| Pyrexia | 9 (23.1) | 0 | 44 (29.1) | 2 (1.3) |
| Fatigue | 14 (35.9) | 1 (2.6) | 40 (26.5) | 3 (2.0) |
| Decreased appetite | 8 (20.5) | 0 | 39 (25.8) | 4 (2.6) |
| PN‡ | 3 (7.7) | 0 | 47 (31.1) | 3 (2.0) |
| AE . | Randomized, BR (n = 39) . | Pooled, pola + BR* (N = 151) . | ||
|---|---|---|---|---|
| All grade . | Grade 3-4 . | All grade . | Grade 3-4 . | |
| Neutropenia | 15 (38.5) | 13 (33.3) | 56 (37.1) | 49 (32.5) |
| Thrombocytopenia | 12 (30.8) | 9 (23.1) | 49 (32.5) | 31 (20.5) |
| Anemia | 10 (25.6) | 7 (17.9) | 49 (32.5) | 19 (12.6) |
| Infections and infestations† | 20 (51.3) | 8 (20.5) | 74 (49.0) | 33 (21.9) |
| Diarrhea | 11 (28.2) | 2 (5.1) | 54 (35.8) | 6 (4.0) |
| Nausea | 16 (41.0) | 0 | 50 (33.1) | 1 (0.7) |
| Pyrexia | 9 (23.1) | 0 | 44 (29.1) | 2 (1.3) |
| Fatigue | 14 (35.9) | 1 (2.6) | 40 (26.5) | 3 (2.0) |
| Decreased appetite | 8 (20.5) | 0 | 39 (25.8) | 4 (2.6) |
| PN‡ | 3 (7.7) | 0 | 47 (31.1) | 3 (2.0) |
Data are presented as n (%). Shown are all-grade AEs occurring in ≥20% of patients and grade 3 to 4 AEs in ≥10% of patients (safety-evaluable population).
Includes all patients with DLBCL who received at least 1 dose of pola + BR.
System organ class grouped term.
Includes PN, peripheral sensory neuropathy, muscular weakness, paresthesia, muscle atrophy, hypoesthesia, gait disturbance, decreased vibratory sense, hypotonia, and neuralgia.